MSD Animal Health and FVE Reward 34 Veterinary Students from Across Europe
February 9, 2026
BRUSSELS, BELGIUM., February 9, 2026 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), and the Federation of Veterinarians of Europe (FVE) are honoured to announce that 34 veterinary students across the European Region have been awarded the 2025 MSD and FVE Veterinary Student Scholarship Program.
The Scholarships for students enrolled in the 3rd-4th-5th year of study allow them to enhance their academic experience and eventually start their careers.
The review committee selected 34 students out of 132 applications. The students are currently enrolled in 25 veterinary faculties from 17 countries: Bulgaria, Denmark, Estonia, Finland, France, Greece, Hungary, Ireland, Italy, Lithuania, Poland, Portugal, Romania, Spain, Sweden, and the United Kingdom.
For the past decade, MSD Animal Health has proudly partnered with FVE. Together, we have awarded scholarships to nearly 400 veterinary students and young professionals through the MSD Animal Health–FVE Scholarship Program.
“We are proud to collaborate with FVE in supporting the next generation of veterinary professionals. It is essential for us to work with organizations that share our commitment to advancing animal health and empowering young talent. This long-standing partnership reflects our dedication to the veterinary community across Europe and beyond,” said Pedro Silva, Senior Vice President, MSD Animal Health, EURAM.
“The successful partnership with MSD Animal Health has allowed us to support and empower 432 veterinary students in the last 10 years, many of whom will surely become young leaders in the veterinary field. ” notes FVE President Siegfried Moder. “We are grateful to MSD Animal Health who allows us to keep investing in students and the future of the profession for the sake of One Health and One Welfare”.
FVE is extremely satisfied with the success of the scholarship and the number of students applying and is extremely grateful to MSD Animal Health for being able to run together again on this important scholarship. FVE wishes to thank the European Association of Establishments for Veterinary Education (EAEVE) for the support in promoting the scholarship and the International Veterinary Students’ Association (IVSA) for their valuable support in the dissemination and selection of the students.
About FVE
The Federation of Veterinarians of Europe (FVE) represents around 300,000 veterinarians across 38 European countries. The Federation of Veterinarians of Europe (FVE) aims to enhance animal health, animal welfare, and public health and to protect the environment by promoting the veterinary profession.
For further information, consult the FVE website www.fve.org – FVE Secretariat info@fve.org
About MSD Animal Health
MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com and connect with us on LinkedIn and X (formerly Twitter). MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is a global animal health business committed to The Science of Healthier Animals™. For more than 130 years, we have pioneered groundbreaking science. Today, we are driven by continuous innovation to develop breakthrough medicines, vaccines and technology. Rooted in direct experience on the farm and in the clinic, we work hand in hand with our customers every step of the way. Our singular focus is to empower those who care for animals, helping them manage their vital responsibility with confidence. Because when it comes to animal health, no one sees it like we do. For more information, visit www.msd-animal-health.com and connect with us on LinkedIn and X (formerly Twitter).
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).